Revance Therapeutics Closes on $45M
Revance Therapeutics Inc., a drug developer focused on dermatology and aesthetic medicine, has raised $45 million in new capital from Essex Woodlands Health Ventures, NovaQuest Capital, CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corporation. Jonathan Tunnicliffe, a partner at NovaQuest, will join the Revance board as a result of the round. Revance closed a $25.62 million in Series D funding in late 2009.
10 June 2011•3 mins read
